Effects on Glutamine on the Outcome of Allogeneic Bone Marrow Transplant Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00563498
Recruitment Status : Unknown
Verified July 2010 by Hospital Authority, Hong Kong.
Recruitment status was:  Recruiting
First Posted : November 26, 2007
Last Update Posted : July 7, 2010
The University of Hong Kong
Fresienius Kabi HK Ltd
Information provided by:
Hospital Authority, Hong Kong

November 21, 2007
November 26, 2007
July 7, 2010
July 2004
Not Provided
  • Veno-occlusive disease [ Time Frame: 1 month ]
  • Mucositis [ Time Frame: 1 month ]
Same as current
Complete list of historical versions of study NCT00563498 on Archive Site
  • Hospital stay [ Time Frame: 2 months ]
  • Use of antibiotics [ Time Frame: 2 months ]
Same as current
Not Provided
Not Provided
Effects on Glutamine on the Outcome of Allogeneic Bone Marrow Transplant Recipients
A Randomized Control Studies on the Effects of Glutamine on the Clinical Outcome of Bone Marrow Transplant Recipients With Special Reference to Veno-occlusive Disease and Mucositis.
The primary purpose of this project is to investigate if addition of glutamine, an amino acid, to standard parenteral nutrition, may improve the clinical outcome of the bone marrrow transplantation reducing the occurrence of veno-occlusive disease and severity of mucositis.
Not Provided
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
  • Pulmonary Veno-Occlusive Disease
  • Hepatic Veno-Occlusive Disease
  • Mucositis
Drug: Glutamine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
June 2006
Not Provided

Inclusion Criteria:

  • Allogeneic bone marrow transplant recipients using busulfan and cyclophosphamide as conditioning.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Not Provided
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Hospital Authority, Hong Kong
  • The University of Hong Kong
  • Fresienius Kabi HK Ltd
Principal Investigator: Albert Lie, Dr Department of Medicine/Division of Haematology, Queen Mary Hospital/ The University of Hong Kong
Hospital Authority, Hong Kong
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP